{"transactions":[{"id":762640,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2026-05-27T23:30:14.000Z","date":"2026-05-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1630,"price":0.1743,"value":284.109,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: 3,031 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 32,633 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":113654,"source":{"system":"sec-edgar","filing":"0002041855-26-000010","document":"form4-05272026_070509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185526000010/form4-05272026_070509.xml","form_type":"4"}},{"id":762639,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43954,"kind":"person","name":"Jain Nikunj","position":1,"cik":"0002089213","reported_name":"Jain Nikunj","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-05-27T23:30:12.000Z","date":"2026-05-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1919,"price":0.1743,"value":334.4817,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: 2,742 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 32,633 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":235292,"source":{"system":"sec-edgar","filing":"0002089213-26-000008","document":"form4-05272026_070507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000208921326000008/form4-05272026_070507.xml","form_type":"4"}},{"id":762662,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2026-05-27T23:30:09.000Z","date":"2026-05-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":4036,"price":0.1743,"value":703.4748,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: 7,214 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 78,750 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":328733,"source":{"system":"sec-edgar","filing":"0001947007-26-000012","document":"form4-05272026_070505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700726000012/form4-05272026_070505.xml","form_type":"4"}},{"id":762638,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER, SECY"}}],"security":"Common Stock","published_at":"2026-05-27T23:30:07.000Z","date":"2026-05-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":4036,"price":0.1743,"value":703.4748,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: 7,214 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 78,750 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":647370,"source":{"system":"sec-edgar","filing":"0001877368-26-000008","document":"form4-05272026_070504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000187736826000008/form4-05272026_070504.xml","form_type":"4"}},{"id":762637,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Common Stock","published_at":"2026-05-27T23:30:05.000Z","date":"2026-05-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":12613,"price":0.1743,"value":2198.4459,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: 22,543 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 246,094 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":1895043,"source":{"system":"sec-edgar","filing":"0001675687-26-000008","document":"form4-05272026_070501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000167568726000008/form4-05272026_070501.xml","form_type":"4"}},{"id":802121,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2026-04-23T20:07:12.000Z","date":"2026-04-22","kind":"sale","planned":false,"acquired":false,"shares":69827,"price":0.2534,"value":17694.1618,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.2533 to $0.2568, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":115284,"source":{"system":"sec-edgar","filing":"0002041855-26-000008","document":"form4-04232026_080406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185526000008/form4-04232026_080406.xml","form_type":"4"}},{"id":802122,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2026-04-23T20:05:40.000Z","date":"2026-04-21","kind":"sale","planned":false,"acquired":false,"shares":345942,"price":0.2578,"value":89183.8476,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.2533 to $0.2634, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":332769,"source":{"system":"sec-edgar","filing":"0001947007-26-000010","document":"form4-04232026_080436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700726000010/form4-04232026_080436.xml","form_type":"4"}},{"id":817536,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:15:20.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":800000,"derivative":{"exercise_price":0.2601,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001947007-26-000006","document":"form4-04032026_040403.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700726000006/form4-04032026_040403.xml","form_type":"4"}},{"id":817527,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43954,"kind":"person","name":"Jain Nikunj","position":1,"cik":"0002089213","reported_name":"Jain Nikunj","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:15:19.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":225000,"derivative":{"exercise_price":0.2601,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0002089213-26-000006","document":"form4-04032026_040411.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000208921326000006/form4-04032026_040411.xml","form_type":"4"}},{"id":817526,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:15:16.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":225000,"derivative":{"exercise_price":0.2601,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0002041855-26-000006","document":"form4-04032026_040407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185526000006/form4-04032026_040407.xml","form_type":"4"}},{"id":817525,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:15:15.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":2500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":2500000,"derivative":{"exercise_price":0.2601,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":2500000},"source":{"system":"sec-edgar","filing":"0001675687-26-000006","document":"form4-04032026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000167568726000006/form4-04032026_040401.xml","form_type":"4"}},{"id":817524,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER, SECY"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T20:15:10.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":800000,"derivative":{"exercise_price":0.2601,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001877368-26-000006","document":"form4-04032026_040405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000187736826000006/form4-04032026_040405.xml","form_type":"4"}},{"id":880421,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:15.000Z","date":"2026-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":12354,"price":0.47,"value":5806.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2026 of $0.47/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes: 17,646 shares from the February 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 90,000 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is\nsubject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":678711,"source":{"system":"sec-edgar","filing":"0001947007-26-000004","document":"form4-02262026_090211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700726000004/form4-02262026_090211.xml","form_type":"4"}},{"id":880420,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:15.000Z","date":"2026-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":2063,"price":0.4725,"value":974.7675,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2026 of $0.4725/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 2,947 shares from the February 24, 2026 vesting installment of the Reporting Person's February 24, 2023 RSU grant and (b) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":691065,"source":{"system":"sec-edgar","filing":"0001947007-26-000004","document":"form4-02262026_090211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700726000004/form4-02262026_090211.xml","form_type":"4"}},{"id":880408,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:14.000Z","date":"2026-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":33637,"price":0.47,"value":15809.39,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2026 of $0.47/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes: 60,113 shares from the February 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 281,250 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":1907656,"source":{"system":"sec-edgar","filing":"0001675687-26-000004","document":"form4-02262026_090209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000167568726000004/form4-02262026_090209.xml","form_type":"4"}},{"id":880407,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:14.000Z","date":"2026-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":5291,"price":0.4725,"value":2499.9975,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2026 of $0.4725/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 9,456 shares from the February 24, 2026 vesting installment of the Reporting Person's February 24, 2023 RSU grant and (b) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":1941293,"source":{"system":"sec-edgar","filing":"0001675687-26-000004","document":"form4-02262026_090209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000167568726000004/form4-02262026_090209.xml","form_type":"4"}},{"id":880406,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER, SECY"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:11.000Z","date":"2026-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":12354,"price":0.47,"value":5806.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2026 of $0.47/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes: 17,646 shares from the February 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 90,000 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":651406,"source":{"system":"sec-edgar","filing":"0001877368-26-000004","document":"form4-02262026_090207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000187736826000004/form4-02262026_090207.xml","form_type":"4"}},{"id":880405,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER, SECY"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:11.000Z","date":"2026-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1650,"price":0.4725,"value":779.625,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2026 of $0.4725/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 2,358 shares from the February 24, 2026 vesting installment of the Reporting Person's February 24, 2023 RSU grant and (b) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":663760,"source":{"system":"sec-edgar","filing":"0001877368-26-000004","document":"form4-02262026_090207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000187736826000004/form4-02262026_090207.xml","form_type":"4"}},{"id":880404,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43954,"kind":"person","name":"Jain Nikunj","position":1,"cik":"0002089213","reported_name":"Jain Nikunj","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:09.000Z","date":"2026-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":5119,"price":0.47,"value":2405.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2026 of $0.47/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes: 7,313 shares from the February 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 37,294 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":237211,"source":{"system":"sec-edgar","filing":"0002089213-26-000004","document":"form4-02262026_090205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000208921326000004/form4-02262026_090205.xml","form_type":"4"}},{"id":880403,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43954,"kind":"person","name":"Jain Nikunj","position":1,"cik":"0002089213","reported_name":"Jain Nikunj","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:09.000Z","date":"2026-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":666,"price":0.4725,"value":314.685,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2026 of $0.4725/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 952 shares from the February 24, 2026 vesting installment of the Reporting Person's February 24, 2023 RSU grant and (b) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":242330,"source":{"system":"sec-edgar","filing":"0002089213-26-000004","document":"form4-02262026_090205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000208921326000004/form4-02262026_090205.xml","form_type":"4"}},{"id":880402,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:07.000Z","date":"2026-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":5119,"price":0.47,"value":2405.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2026 of $0.47/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes: 7,313 shares from the February 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 37,294 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":185111,"source":{"system":"sec-edgar","filing":"0002041855-26-000004","document":"form4-02262026_090201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185526000004/form4-02262026_090201.xml","form_type":"4"}},{"id":880401,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2026-02-27T02:40:07.000Z","date":"2026-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":832,"price":0.4725,"value":393.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2026 of $0.4725/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,190 shares from the February 24, 2026 vesting installment of the Reporting Person's February 24, 2023 RSU grant and (b) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":190230,"source":{"system":"sec-edgar","filing":"0002041855-26-000004","document":"form4-02262026_090201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185526000004/form4-02262026_090201.xml","form_type":"4"}},{"id":931454,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43954,"kind":"person","name":"Jain Nikunj","position":1,"cik":"0002089213","reported_name":"Jain Nikunj","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-01-26T21:14:59.000Z","date":"2026-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":7721,"price":0.3985,"value":3076.8185,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 11,029 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 1,618 shares subject Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,000 shares acquired on November 28, 2025 under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":242996,"source":{"system":"sec-edgar","filing":"0002089213-26-000002","document":"form4-01262026_090156.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000208921326000002/form4-01262026_090156.xml","form_type":"4"}},{"id":931452,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":65373,"kind":"person","name":"Duraibabu Prathyusha","position":1,"cik":"0001779092","reported_name":"Duraibabu Prathyusha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-01-26T21:13:32.000Z","date":"2026-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":36676,"price":0.3985,"value":14615.386,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 52,387 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 5,010 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":660042,"source":{"system":"sec-edgar","filing":"0001779092-26-000002","document":"form4-01262026_090129.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000177909226000002/form4-01262026_090129.xml","form_type":"4"}},{"id":931450,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER, SECY"}}],"security":"Common Stock","published_at":"2026-01-26T21:12:07.000Z","date":"2026-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":36676,"price":0.3985,"value":14615.386,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: 52,387 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 4,008 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":665410,"source":{"system":"sec-edgar","filing":"0001877368-26-000002","document":"form4-01262026_090103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000187736826000002/form4-01262026_090103.xml","form_type":"4"}},{"id":931451,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Common Stock","published_at":"2026-01-26T21:10:26.000Z","date":"2026-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":102950,"price":0.3985,"value":41025.575,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 147,050 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 14,747 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":1946584,"source":{"system":"sec-edgar","filing":"0001675687-26-000002","document":"form4-01262026_090123.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000167568726000002/form4-01262026_090123.xml","form_type":"4"}},{"id":931449,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2026-01-26T21:08:45.000Z","date":"2026-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":7721,"price":0.3985,"value":3076.8185,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 11,029 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 2,022 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,000 shares acquired on May 30, 2025 under the Issuer's 2020 Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The Reporting Person previously transferred 8 shares of the Issuer's common stock to his ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse."}],"balance_after":191062,"source":{"system":"sec-edgar","filing":"0002041855-26-000002","document":"form4-01262026_090141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185526000002/form4-01262026_090141.xml","form_type":"4"}},{"id":931453,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2026-01-26T21:06:47.000Z","date":"2026-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":36676,"price":0.3985,"value":14615.386,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 52,387 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 5,010 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,000 shares acquired on May 30, 2025 and 5,000 shares acquired on November 28, 2025 under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":693128,"source":{"system":"sec-edgar","filing":"0001947007-26-000002","document":"form4-01262026_090143.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700726000002/form4-01262026_090143.xml","form_type":"4"}},{"id":987748,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43954,"kind":"person","name":"Jain Nikunj","position":1,"cik":"0002089213","reported_name":"Jain Nikunj","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2025-11-26T21:10:22.000Z","date":"2025-11-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":578,"price":0.4166,"value":240.7948,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on November 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2025 of $0.4166/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,039 shares from the November 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 1,618 shares will vest on February 24, 2026, (b) 18,750 shares subject Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026, and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":245717,"source":{"system":"sec-edgar","filing":"0002089213-25-000008","document":"form4-11262025_091117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000208921325000008/form4-11262025_091117.xml","form_type":"4"}},{"id":987747,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER, SECY"}}],"security":"Common Stock","published_at":"2025-11-26T21:09:24.000Z","date":"2025-11-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":2035,"price":0.4166,"value":847.781,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on November 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2025 of $0.4166/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,973 shares resulting from the November 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 4,008  shares will vest on February 24, 2026, (b) 89,063 shares subject to Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":702086,"source":{"system":"sec-edgar","filing":"0001877368-25-000007","document":"form4-11262025_091119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000187736825000007/form4-11262025_091119.xml","form_type":"4"}},{"id":987746,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-11-26T21:08:23.000Z","date":"2025-11-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":7488,"price":0.4166,"value":3119.5008,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on November 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2025 of $0.4166/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 7,259 shares resulting from the November 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 14,747 shares will vest on February 24, 2026, (b) 250,000 shares subject to Reporting Person's January 22, 2024 RSU grant will vest in successive equal quarterly installments through January 22, 2026, (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":2049534,"source":{"system":"sec-edgar","filing":"0001675687-25-000008","document":"form4-11262025_091118.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000167568725000008/form4-11262025_091118.xml","form_type":"4"}},{"id":987744,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":65373,"kind":"person","name":"Duraibabu Prathyusha","position":1,"cik":"0001779092","reported_name":"Duraibabu Prathyusha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-11-26T21:07:19.000Z","date":"2025-11-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":2544,"price":0.4166,"value":1059.8304,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on November 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2025 of $0.4166/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 2,466 shares resulting from the November 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 5,010 shares will vest on February 24, 2026, (b) 89,063 shares subject to Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":696718,"source":{"system":"sec-edgar","filing":"0001779092-25-000007","document":"form4-11262025_091116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000177909225000007/form4-11262025_091116.xml","form_type":"4"}},{"id":987862,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-11-26T21:06:19.000Z","date":"2025-11-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":2544,"price":0.4166,"value":1059.8304,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on November 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2025 of $0.4166/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: 2,466 shares resulting from the November 24, 2025 vesting installment of the Reporting Person's\nFebruary 24, 2023 RSU grant, and the remaining 5,010 shares will vest on February 24, 2026, (b) 89,063 shares subject to Reporting Person's January 22, 2024 RSU grant will vest in successive equal quarterly installments through January 22, 2026, (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":719804,"source":{"system":"sec-edgar","filing":"0001947007-25-000006","document":"form4-11262025_091116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700725000006/form4-11262025_091116.xml","form_type":"4"}},{"id":987745,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-11-26T21:05:09.000Z","date":"2025-11-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":723,"price":0.4166,"value":301.2018,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on November 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2025 of $0.4166/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,298 shares from the November 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 2,022 shares will vest on February 24, 2026, (b) 18,750 shares subject to Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026, and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":193791,"source":{"system":"sec-edgar","filing":"0002041855-25-000006","document":"form4-11262025_091103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185525000006/form4-11262025_091103.xml","form_type":"4"}},{"id":1013993,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-10-24T21:00:14.000Z","date":"2025-10-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":43741,"price":0.66,"value":28869.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 45,321 shares resulting from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 89,063 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 10,020 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":722348,"source":{"system":"sec-edgar","filing":"0001947007-25-000004","document":"form4-10242025_051010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000194700725000004/form4-10242025_051010.xml","form_type":"4"}},{"id":1013991,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER, SECY"}}],"security":"Common Stock","published_at":"2025-10-24T21:00:12.000Z","date":"2025-10-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":44122,"price":0.66,"value":29120.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 44,940 shares resulting from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 89,063 shares will vest in successive equal quarterly installments through January 22, 2026, (b)  8,016 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":704121,"source":{"system":"sec-edgar","filing":"0001877368-25-000005","document":"form4-10242025_051009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000187736825000005/form4-10242025_051009.xml","form_type":"4"}},{"id":1013992,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-10-24T21:00:10.000Z","date":"2025-10-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":126950,"price":0.66,"value":83787.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 123,050 shares resulting from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 250,000 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 29,494 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":2057022,"source":{"system":"sec-edgar","filing":"0001675687-25-000006","document":"form4-10242025_051007.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000167568725000006/form4-10242025_051007.xml","form_type":"4"}},{"id":1013990,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":65373,"kind":"person","name":"Duraibabu Prathyusha","position":1,"cik":"0001779092","reported_name":"Duraibabu Prathyusha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRINCIPAL FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-10-24T21:00:09.000Z","date":"2025-10-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":45225,"price":0.66,"value":29848.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 43,837 shares resulting from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 89,063 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 10,020 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":699262,"source":{"system":"sec-edgar","filing":"0001779092-25-000005","document":"form4-10242025_051005.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000177909225000005/form4-10242025_051005.xml","form_type":"4"}},{"id":1013989,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43954,"kind":"person","name":"Jain Nikunj","position":1,"cik":"0002089213","reported_name":"Jain Nikunj","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2025-10-24T21:00:07.000Z","date":"2025-10-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":6708,"price":0.66,"value":4427.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 12,042 shares from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 18,750 shares that will vest in successive equal quarterly installments through January 22, 2026, (b) 3,235 shares subject Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":246295,"source":{"system":"sec-edgar","filing":"0002089213-25-000006","document":"form4-10242025_051003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000208921325000006/form4-10242025_051003.xml","form_type":"4"}},{"id":1013988,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-10-24T21:00:05.000Z","date":"2025-10-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":6708,"price":0.66,"value":4427.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 12,042 shares from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 18,750 shares that will vest in successive equal quarterly installments through January 22, 2026, (b) 4,043 shares subject Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":194514,"source":{"system":"sec-edgar","filing":"0002041855-25-000004","document":"form4-10242025_051001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000204185525000004/form4-10242025_051001.xml","form_type":"4"}},{"id":1056123,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-08-27T00:05:16.000Z","date":"2025-08-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":7488,"price":0.5863,"value":4390.2144,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on August 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 22, 2025 of $0.5863/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 7,259 shares resulting from the August 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 29,494 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 500,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":2183972,"source":{"system":"sec-edgar","filing":"0001415889-25-023081","document":"form4-08272025_120812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925023081/form4-08272025_120812.xml","form_type":"4"}},{"id":1056122,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-08-27T00:03:33.000Z","date":"2025-08-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":723,"price":0.5863,"value":423.8949,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on August 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 22, 2025 of $0.5863/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,299 shares resulting from the August 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 4,043 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 37,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":201222,"source":{"system":"sec-edgar","filing":"0001415889-25-023079","document":"form4-08272025_120830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925023079/form4-08272025_120830.xml","form_type":"4"}},{"id":1056121,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER, SECY"}}],"security":"Common Stock","published_at":"2025-08-27T00:01:34.000Z","date":"2025-08-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1434,"price":0.5863,"value":840.7542,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on August 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 22, 2025 of $0.5863/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 2,574 shares resulting from the August 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 8,016 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 178,125 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":748243,"source":{"system":"sec-edgar","filing":"0001415889-25-023077","document":"form4-08272025_120830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925023077/form4-08272025_120830.xml","form_type":"4"}},{"id":1056120,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":65373,"kind":"person","name":"Duraibabu Prathyusha","position":1,"cik":"0001779092","reported_name":"Duraibabu Prathyusha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-08-27T00:00:14.000Z","date":"2025-08-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1792,"price":0.5863,"value":1050.6496,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on August 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 22, 2025 of $0.5863/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,218 shares resulting from the August 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 10,020 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 178,125 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":744487,"source":{"system":"sec-edgar","filing":"0001415889-25-023074","document":"form4-08272025_120810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925023074/form4-08272025_120810.xml","form_type":"4"}},{"id":1056133,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-08-26T23:59:09.000Z","date":"2025-08-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1792,"price":0.5863,"value":1050.6496,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on August 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 22, 2025 of $0.5863/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,218 shares resulting from the August 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 10,020 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 178,125 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":766089,"source":{"system":"sec-edgar","filing":"0001415889-25-023071","document":"form4-08262025_110806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925023071/form4-08262025_110806.xml","form_type":"4"}},{"id":1082408,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":65373,"kind":"person","name":"Duraibabu Prathyusha","position":1,"cik":"0001779092","reported_name":"Duraibabu Prathyusha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-07-24T20:59:23.000Z","date":"2025-07-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":31866,"price":0.4798,"value":15289.3068,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on July 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on July 22, 2025 of $0.4798/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 57,197 shares resulting from the July 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 178,125 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 15,030 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":746279,"source":{"system":"sec-edgar","filing":"0001415889-25-020246","document":"form4-07242025_080720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925020246/form4-07242025_080720.xml","form_type":"4"}},{"id":1082409,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-07-24T20:58:36.000Z","date":"2025-07-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":126950,"price":0.4798,"value":60910.61,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on July 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on July 22, 2025 of $0.4798/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 123,050 shares resulting from the July 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 500,000 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 44,241 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":2191460,"source":{"system":"sec-edgar","filing":"0001415889-25-020245","document":"form4-07242025_080733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925020245/form4-07242025_080733.xml","form_type":"4"}},{"id":1082407,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER, SECY"}}],"security":"Common Stock","published_at":"2025-07-24T20:57:27.000Z","date":"2025-07-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":31866,"price":0.4798,"value":15289.3068,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on July 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on July 22, 2025 of $0.4798/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 57,197 shares resulting from the July 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 178,125 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 12,024 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":749677,"source":{"system":"sec-edgar","filing":"0001415889-25-020244","document":"form4-07242025_080724.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925020244/form4-07242025_080724.xml","form_type":"4"}},{"id":1082412,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-07-24T20:56:27.000Z","date":"2025-07-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":31866,"price":0.4798,"value":15289.3068,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on July 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on July 22, 2025 of $0.4798/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 57,197 shares resulting from the July 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 178,125 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 15,030 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":767881,"source":{"system":"sec-edgar","filing":"0001415889-25-020243","document":"form4-07242025_080724.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925020243/form4-07242025_080724.xml","form_type":"4"}},{"id":1082406,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-07-24T20:55:05.000Z","date":"2025-07-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":6708,"price":0.4798,"value":3218.4984,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on July 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on July 22, 2025 of $0.4798/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 12,042 shares resulting from the July 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 37,500 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 6,065 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":201945,"source":{"system":"sec-edgar","filing":"0001415889-25-020242","document":"form4-07242025_080701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925020242/form4-07242025_080701.xml","form_type":"4"}},{"id":1110382,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:05:23.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":50000,"derivative":{"exercise_price":0.503,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-017374","document":"form4-06162025_040615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017374/form4-06162025_040615.xml","form_type":"4"}},{"id":1110381,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":35091,"kind":"person","name":"Smith Karen L.","position":1,"cik":"0001639637","reported_name":"Smith Karen L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T20:05:23.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":102100,"source":{"system":"sec-edgar","filing":"0001415889-25-017374","document":"form4-06162025_040615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017374/form4-06162025_040615.xml","form_type":"4"}},{"id":1110380,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":36743,"kind":"person","name":"PARKER H STEWART","position":1,"cik":"0001217456","reported_name":"PARKER H STEWART","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:05:22.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":50000,"derivative":{"exercise_price":0.503,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-017373","document":"form4-06162025_040613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017373/form4-06162025_040613.xml","form_type":"4"}},{"id":1110379,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":36743,"kind":"person","name":"PARKER H STEWART","position":1,"cik":"0001217456","reported_name":"PARKER H STEWART","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T20:05:22.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":112600,"source":{"system":"sec-edgar","filing":"0001415889-25-017373","document":"form4-06162025_040613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017373/form4-06162025_040613.xml","form_type":"4"}},{"id":1110378,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":16123,"kind":"person","name":"Meyers James R","position":1,"cik":"0001387521","reported_name":"Meyers James R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:05:15.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":50000,"derivative":{"exercise_price":0.503,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-017372","document":"form4-06162025_040611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017372/form4-06162025_040611.xml","form_type":"4"}},{"id":1110377,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":16123,"kind":"person","name":"Meyers James R","position":1,"cik":"0001387521","reported_name":"Meyers James R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T20:05:15.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":99600,"source":{"system":"sec-edgar","filing":"0001415889-25-017372","document":"form4-06162025_040611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017372/form4-06162025_040611.xml","form_type":"4"}},{"id":1110376,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":78480,"kind":"person","name":"Hillan Kenneth J.","position":1,"cik":"0001600359","reported_name":"Hillan Kenneth J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:05:14.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":50000,"derivative":{"exercise_price":0.503,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-017369","document":"form4-06162025_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017369/form4-06162025_040605.xml","form_type":"4"}},{"id":1110375,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":78480,"kind":"person","name":"Hillan Kenneth J.","position":1,"cik":"0001600359","reported_name":"Hillan Kenneth J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T20:05:14.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":99600,"source":{"system":"sec-edgar","filing":"0001415889-25-017369","document":"form4-06162025_040605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017369/form4-06162025_040605.xml","form_type":"4"}},{"id":1110374,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":30083,"kind":"person","name":"Markels John","position":1,"cik":"0001803424","reported_name":"Markels John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:05:13.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":50000,"derivative":{"exercise_price":0.503,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-017371","document":"form4-06162025_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017371/form4-06162025_040609.xml","form_type":"4"}},{"id":1110373,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":30083,"kind":"person","name":"Markels John","position":1,"cik":"0001803424","reported_name":"Markels John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T20:05:13.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":96384,"source":{"system":"sec-edgar","filing":"0001415889-25-017371","document":"form4-06162025_040609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017371/form4-06162025_040609.xml","form_type":"4"}},{"id":1110372,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":73432,"kind":"person","name":"Carey Robert","position":1,"cik":"0001602064","reported_name":"Carey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:05:12.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":50000,"derivative":{"exercise_price":0.503,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-017368","document":"form4-06162025_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017368/form4-06162025_040603.xml","form_type":"4"}},{"id":1110371,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":73432,"kind":"person","name":"Carey Robert","position":1,"cik":"0001602064","reported_name":"Carey Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T20:05:12.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":99600,"source":{"system":"sec-edgar","filing":"0001415889-25-017368","document":"form4-06162025_040603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017368/form4-06162025_040603.xml","form_type":"4"}},{"id":1110370,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":37201,"kind":"person","name":"Horn Margaret A","position":1,"cik":"0001294192","reported_name":"Horn Margaret A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:05:10.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":50000,"derivative":{"exercise_price":0.503,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-017370","document":"form4-06162025_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017370/form4-06162025_040607.xml","form_type":"4"}},{"id":1110369,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":37201,"kind":"person","name":"Horn Margaret A","position":1,"cik":"0001294192","reported_name":"Horn Margaret A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T20:05:10.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,251 shares subject to the Reporting Person's December 15, 2022 RSU grant that will vest in one final  installment on December 15, 2025."}],"balance_after":82650,"source":{"system":"sec-edgar","filing":"0001415889-25-017370","document":"form4-06162025_040607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017370/form4-06162025_040607.xml","form_type":"4"}},{"id":1110368,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":78479,"kind":"person","name":"Beers Courtney","position":1,"cik":"0001955191","reported_name":"Beers Courtney","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:05:07.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":50000,"derivative":{"exercise_price":0.503,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-017367","document":"form4-06162025_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017367/form4-06162025_040601.xml","form_type":"4"}},{"id":1110367,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":78479,"kind":"person","name":"Beers Courtney","position":1,"cik":"0001955191","reported_name":"Beers Courtney","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T20:05:07.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,251 shares subject to the Reporting Person's December 15, 2022 RSU grant that will vest in one final installment on December 15, 2025."}],"balance_after":82650,"source":{"system":"sec-edgar","filing":"0001415889-25-017367","document":"form4-06162025_040601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925017367/form4-06162025_040601.xml","form_type":"4"}},{"id":1132472,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-05-28T20:05:12.000Z","date":"2025-05-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":723,"price":0.4733,"value":342.1959,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on May 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 23, 2025 of $0.4733/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,298 shares resulting from the May 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 6,065 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 56,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":208653,"source":{"system":"sec-edgar","filing":"0001415889-25-014696","document":"form4-05282025_040509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925014696/form4-05282025_040509.xml","form_type":"4"}},{"id":1132471,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER, SECY"}}],"security":"Common Stock","published_at":"2025-05-28T20:05:11.000Z","date":"2025-05-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1433,"price":0.4733,"value":678.2389,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on May 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 23, 2025 of $0.4733/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 2,574 shares resulting from the May 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 12,024 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 267,188 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":781543,"source":{"system":"sec-edgar","filing":"0001415889-25-014695","document":"form4-05282025_040508.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925014695/form4-05282025_040508.xml","form_type":"4"}},{"id":1132473,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-05-28T20:05:09.000Z","date":"2025-05-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1792,"price":0.4733,"value":848.1536,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on May 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 23, 2025 of $0.4733/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,217 shares resulting from the May 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 15,030 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 267,188 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":799747,"source":{"system":"sec-edgar","filing":"0001415889-25-014694","document":"form4-05282025_040506.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925014694/form4-05282025_040506.xml","form_type":"4"}},{"id":1132470,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":65373,"kind":"person","name":"Duraibabu Prathyusha","position":1,"cik":"0001779092","reported_name":"Duraibabu Prathyusha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-05-28T20:05:08.000Z","date":"2025-05-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1792,"price":0.4733,"value":848.1536,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on May 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 23, 2025 of $0.4733/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,217 shares resulting from the May 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 15,030 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 267,188 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":778145,"source":{"system":"sec-edgar","filing":"0001415889-25-014693","document":"form4-05282025_040504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925014693/form4-05282025_040504.xml","form_type":"4"}},{"id":1132469,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-05-28T20:05:05.000Z","date":"2025-05-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":7488,"price":0.4733,"value":3544.0704,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on May 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 23, 2025 of $0.4733/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 7,259 shares resulting from the May 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 44,241 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 750,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":2318410,"source":{"system":"sec-edgar","filing":"0001415889-25-014692","document":"form4-05282025_040502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925014692/form4-05282025_040502.xml","form_type":"4"}},{"id":1166724,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GEN. COUNSEL & SECRETARY"}}],"security":"Common Stock","published_at":"2025-04-24T20:10:48.000Z","date":"2025-04-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":31866,"price":0.7763,"value":24737.5758,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on April 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on April 22, 2025 of $0.7763/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 57,196 shares resulting from the April 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 267,188 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 16,031 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":782976,"source":{"system":"sec-edgar","filing":"0001415889-25-011287","document":"form4-04242025_080444.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925011287/form4-04242025_080444.xml","form_type":"4"}},{"id":1166722,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":65373,"kind":"person","name":"Duraibabu Prathyusha","position":1,"cik":"0001779092","reported_name":"Duraibabu Prathyusha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-04-24T20:09:40.000Z","date":"2025-04-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":31866,"price":0.7763,"value":24737.5758,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on April 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on April 22, 2025 of $0.7763/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 57,196 shares resulting from the April 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 267,188 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":779937,"source":{"system":"sec-edgar","filing":"0001415889-25-011285","document":"form4-04242025_080437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925011285/form4-04242025_080437.xml","form_type":"4"}},{"id":1166721,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-04-24T20:08:28.000Z","date":"2025-04-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":126950,"price":0.7763,"value":98551.285,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on April 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on April 22, 2025 of $0.7763/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 123,050 shares resulting from the April 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 750,000 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 58,988 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":2325898,"source":{"system":"sec-edgar","filing":"0001415889-25-011283","document":"form4-04242025_080425.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925011283/form4-04242025_080425.xml","form_type":"4"}},{"id":1166723,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-04-24T20:07:02.000Z","date":"2025-04-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":31866,"price":0.7763,"value":24737.5758,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on April 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on April 22, 2025 of $0.7763/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 57,196 shares resulting from the April 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 267,188 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares subject to the grant on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":801539,"source":{"system":"sec-edgar","filing":"0001415889-25-011281","document":"form4-04242025_080459.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925011281/form4-04242025_080459.xml","form_type":"4"}},{"id":1166720,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-04-24T20:05:13.000Z","date":"2025-04-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":6708,"price":0.7763,"value":5207.4204,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on April 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on April 22, 2025 of $0.7763/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 12,042 shares resulting from the April 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 56,250 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 8,086 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":209376,"source":{"system":"sec-edgar","filing":"0001415889-25-011279","document":"form4-04242025_080410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925011279/form4-04242025_080410.xml","form_type":"4"}},{"id":1244033,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T22:33:13.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":99454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":99454,"derivative":{"exercise_price":0.9561,"expiration_date":"2035-02-24","underlying":"Common Stock","underlying_shares":99454},"source":{"system":"sec-edgar","filing":"0001415889-25-005708","document":"form4-02262025_100209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005708/form4-02262025_100209.xml","form_type":"4"}},{"id":1244032,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-02-26T22:33:13.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":49726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock issuable upon settlement of a RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes: (a) 8,086 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, (b) 75,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":216084,"source":{"system":"sec-edgar","filing":"0001415889-25-005708","document":"form4-02262025_100209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005708/form4-02262025_100209.xml","form_type":"4"}},{"id":1244031,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-02-26T22:33:13.000Z","date":"2025-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":507,"price":0.9561,"value":484.7427,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2025 of $0.9561/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes: (a) 911 shares resulting from the February 25, 2025 final vesting installment of the Reporting Person's February 25, 2022 RSU grant, (b) 8,086 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, and (c) 75,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":166358,"source":{"system":"sec-edgar","filing":"0001415889-25-005708","document":"form4-02262025_100209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005708/form4-02262025_100209.xml","form_type":"4"}},{"id":1244030,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-02-26T22:33:13.000Z","date":"2025-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":705,"price":1,"value":705.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2025 of $1.00/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 1,317 shares resulting from the February 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 8,086 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 1,418 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025 and (c) 75,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":166865,"source":{"system":"sec-edgar","filing":"0001415889-25-005708","document":"form4-02262025_100209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005708/form4-02262025_100209.xml","form_type":"4"}},{"id":1244037,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T22:32:37.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":560000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":560000,"derivative":{"exercise_price":0.9561,"expiration_date":"2035-02-24","underlying":"Common Stock","underlying_shares":560000},"source":{"system":"sec-edgar","filing":"0001415889-25-005707","document":"form4-02262025_100233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925005707/form4-02262025_100233.xml","form_type":"4"}},{"id":1244036,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-02-26T22:32:37.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock issuable upon settlement of a RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes: (a) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, (b) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":833405,"source":{"system":"sec-edgar","filing":"0001415889-25-005707","document":"form4-02262025_100233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925005707/form4-02262025_100233.xml","form_type":"4"}},{"id":1244035,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-02-26T22:32:37.000Z","date":"2025-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1513,"price":0.9561,"value":1446.5793,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2025 of $0.9561/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes: (a) 2,716 shares resulting from the February 25, 2025 final vesting installment of the Reporting Person's February 25, 2022 RSU grant, (b) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":713405,"source":{"system":"sec-edgar","filing":"0001415889-25-005707","document":"form4-02262025_100233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925005707/form4-02262025_100233.xml","form_type":"4"}},{"id":1244034,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-02-26T22:32:37.000Z","date":"2025-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1792,"price":1,"value":1792.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2025 of $1.00/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,218 shares resulting from the February 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 20,039 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 4,229 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025, and (c) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":714918,"source":{"system":"sec-edgar","filing":"0001415889-25-005707","document":"form4-02262025_100233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925005707/form4-02262025_100233.xml","form_type":"4"}},{"id":1244029,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GEN. COUNSEL & SECRETARY"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T22:32:04.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":560000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":560000,"derivative":{"exercise_price":0.9561,"expiration_date":"2035-02-24","underlying":"Common Stock","underlying_shares":560000},"source":{"system":"sec-edgar","filing":"0001415889-25-005706","document":"form4-02262025_100200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005706/form4-02262025_100200.xml","form_type":"4"}},{"id":1244028,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GEN. COUNSEL & SECRETARY"}}],"security":"Common Stock","published_at":"2025-02-26T22:32:04.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock issuable upon settlement of a RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes: (a) 16,031 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, (b) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":814842,"source":{"system":"sec-edgar","filing":"0001415889-25-005706","document":"form4-02262025_100200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005706/form4-02262025_100200.xml","form_type":"4"}},{"id":1244027,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GEN. COUNSEL & SECRETARY"}}],"security":"Common Stock","published_at":"2025-02-26T22:32:04.000Z","date":"2025-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1375,"price":0.9561,"value":1314.6375,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2025 of $0.9561/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes: (a) 2,469 shares resulting from the February 25, 2025 final vesting installment of the Reporting Person's February 25, 2022 RSU grant, (b) 16,031 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, and (c) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":694842,"source":{"system":"sec-edgar","filing":"0001415889-25-005706","document":"form4-02262025_100200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005706/form4-02262025_100200.xml","form_type":"4"}},{"id":1244026,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GEN. COUNSEL & SECRETARY"}}],"security":"Common Stock","published_at":"2025-02-26T22:32:04.000Z","date":"2025-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1434,"price":1,"value":1434.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2025 of $1.00/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 2,574 shares resulting from the February 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 16,031 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 3,844 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025 and (c) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":696217,"source":{"system":"sec-edgar","filing":"0001415889-25-005706","document":"form4-02262025_100200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005706/form4-02262025_100200.xml","form_type":"4"}},{"id":1244025,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":65373,"kind":"person","name":"Duraibabu Prathyusha","position":1,"cik":"0001779092","reported_name":"Duraibabu Prathyusha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T22:31:20.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":560000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":560000,"derivative":{"exercise_price":0.9561,"expiration_date":"2035-02-24","underlying":"Common Stock","underlying_shares":560000},"source":{"system":"sec-edgar","filing":"0001415889-25-005705","document":"form4-02262025_100216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005705/form4-02262025_100216.xml","form_type":"4"}},{"id":1244024,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":65373,"kind":"person","name":"Duraibabu Prathyusha","position":1,"cik":"0001779092","reported_name":"Duraibabu Prathyusha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-26T22:31:20.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock issuable upon settlement of a RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes: (a) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, (b) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":811803,"source":{"system":"sec-edgar","filing":"0001415889-25-005705","document":"form4-02262025_100216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005705/form4-02262025_100216.xml","form_type":"4"}},{"id":1244023,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":65373,"kind":"person","name":"Duraibabu Prathyusha","position":1,"cik":"0001779092","reported_name":"Duraibabu Prathyusha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-26T22:31:20.000Z","date":"2025-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1375,"price":0.9561,"value":1314.6375,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2025 of $0.9561/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes:(a) 2,469 shares resulting from the February 25, 2025 final vesting installment of the Reporting Person's February 25, 2022 RSU grant, (b) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":691803,"source":{"system":"sec-edgar","filing":"0001415889-25-005705","document":"form4-02262025_100216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005705/form4-02262025_100216.xml","form_type":"4"}},{"id":1244022,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":65373,"kind":"person","name":"Duraibabu Prathyusha","position":1,"cik":"0001779092","reported_name":"Duraibabu Prathyusha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-26T22:31:20.000Z","date":"2025-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1792,"price":1,"value":1792.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2025 of $1.00/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,218 shares resulting from the February 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 20,039 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 3,844 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final quarterly installment on February 25, 2025, and (c) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":693178,"source":{"system":"sec-edgar","filing":"0001415889-25-005705","document":"form4-02262025_100216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005705/form4-02262025_100216.xml","form_type":"4"}},{"id":1244021,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T22:30:33.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":1750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":1750000,"derivative":{"exercise_price":0.9561,"expiration_date":"2035-02-24","underlying":"Common Stock","underlying_shares":1750000},"source":{"system":"sec-edgar","filing":"0001415889-25-005704","document":"form4-02262025_100229.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005704/form4-02262025_100229.xml","form_type":"4"}},{"id":1244020,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-02-26T22:30:33.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock issuable upon settlement of a RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes: (a) 58,988 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, (b) 1,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":2452848,"source":{"system":"sec-edgar","filing":"0001415889-25-005704","document":"form4-02262025_100229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005704/form4-02262025_100229.xml","form_type":"4"}},{"id":1244019,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-02-26T22:30:33.000Z","date":"2025-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":10663,"price":0.9561,"value":10194.8943,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares underlying the portion of an RSU grant that vested on February 25, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2025 of $0.9561/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes: (a) 10,337 shares resulting from the February 25, 2025 final vesting installment of the Reporting Person's February 25, 2022 RSU grant, (b) 58,988 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 1,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":2077848,"source":{"system":"sec-edgar","filing":"0001415889-25-005704","document":"form4-02262025_100229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005704/form4-02262025_100229.xml","form_type":"4"}},{"id":1244018,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43952,"kind":"person","name":"Macrae Sandy","position":1,"cik":"0001675687","reported_name":"Macrae Sandy","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-02-26T22:30:33.000Z","date":"2025-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":7488,"price":1,"value":7488.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on February 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2025 of $1.00/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 7,259 shares resulting from the February 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 58,988 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 21,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final quarterly installment on February 25, 2025 and (c) 1,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":2088511,"source":{"system":"sec-edgar","filing":"0001415889-25-005704","document":"form4-02262025_100229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925005704/form4-02262025_100229.xml","form_type":"4"}},{"id":1295888,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43955,"kind":"person","name":"Davis Gregory D","position":1,"cik":"0002041855","reported_name":"Davis Gregory D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of Research & Technology"}}],"security":"Common Stock","published_at":"2025-01-24T21:05:16.000Z","date":"2025-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":30456,"price":1.15,"value":35024.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2025 of $1.15/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 44,544 shares resulting from the January 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 75,000 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 1,418 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025 and (c) 10,108 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,000 shares acquired on November 29, 2024 under the Issuer's 2020 Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Since the date of the Reporting Person's last ownership report, he transferred 8,837 shares of common stock to his ex-spouse pursuant to a divorce agreement. The Reporting Person no longer reports as beneficially owned any securities transferred to his ex-spouse."}],"balance_after":167570,"source":{"system":"sec-edgar","filing":"0001415889-25-002022","document":"form4-01242025_040112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925002022/form4-01242025_040112.xml","form_type":"4"}},{"id":1295889,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43957,"kind":"person","name":"Dubois-Stringfellow Nathalie","position":1,"cik":"0001947007","reported_name":"Dubois-Stringfellow Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP-CHIEF DEVELOPMENT OFFICER"}}],"security":"Common Stock","published_at":"2025-01-24T21:05:15.000Z","date":"2025-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":129593,"price":1.15,"value":149031.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2025 of $1.15/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 226,657 shares resulting from the January 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 356,250 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 4,229 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025 and (c) 25,049 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,000 shares acquired on November 29, 2024 under the Issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":716710,"source":{"system":"sec-edgar","filing":"0001415889-25-002020","document":"form4-01242025_040107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1947007/000141588925002020/form4-01242025_040107.xml","form_type":"4"}},{"id":1295887,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":43953,"kind":"person","name":"Willoughby Scott B.","position":1,"cik":"0001877368","reported_name":"Willoughby Scott B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GEN. COUNSEL & SECRETARY"}}],"security":"Common Stock","published_at":"2025-01-24T21:05:14.000Z","date":"2025-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":129549,"price":1.15,"value":148981.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2025 of $1.15/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 226,701 shares resulting from the January 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 356,250 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 3,844 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025 and (c) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":697651,"source":{"system":"sec-edgar","filing":"0001415889-25-002021","document":"form4-01242025_040110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925002021/form4-01242025_040110.xml","form_type":"4"}},{"id":1295886,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":65373,"kind":"person","name":"Duraibabu Prathyusha","position":1,"cik":"0001779092","reported_name":"Duraibabu Prathyusha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-24T21:05:13.000Z","date":"2025-01-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":129242,"price":1.15,"value":148628.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on January 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2025 of $1.15/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 227,008 shares resulting from the January 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 356,250 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 3,844 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025 and (c) 25,049 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":694970,"source":{"system":"sec-edgar","filing":"0001415889-25-002019","document":"form4-01242025_040104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000141588925002019/form4-01242025_040104.xml","form_type":"4"}}],"next_cursor":"2025-01-24T21:05:13.000000Z,1295886"}